Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Roche's Guide To Success In Oncology

Executive Summary

Roche's potential in the growing field of immuno-oncology has been a game of wait and see. But now that Tecentriq has launched, the company believes the components are in place to maintain its leadership position in oncology.


Related Content

How Immuno-Oncology Is Turning Biomarker Development On Its Head
PDUFA VI: A Machine To Speed R&D Time, Cut Costs
Roche Sees Cancer Combos Start To Deliver
Bristol Pushes Pedal To Metal In Immuno-Oncology Combo Testing
Engineering Roche’s Next Big Thing: Bispecific Antibodies And Beyond
For Roche Immuno-Oncology, It’s Steady As She Goes
Pharma trial needs drive Roche's $1.2bn Foundation Medicine deal


Related Companies